Dunn P J, Cole R A, Soeldner J S, Gleason R E
J Clin Endocrinol Metab. 1981 May;52(5):1019-22. doi: 10.1210/jcem-52-5-1019.
Hemoglobin (Hb) AIc levels were measured biweekly for 14 weeks in 49 diabetic out-patients and 20 nondiabetic subjects. As conventional indices of diabetes control, urine tests were performed four times per day, and plasma glucose concentrations were measured 2 h post breakfast. The diabetic group ranged in age from 15-73 yr and in duration of diabetes from 6 months to 45 yr. Eleven subjects were on diet therapy alone, three were on oral hypoglycemic agents, and 35 were on insulin therapy. The nondiabetic group ranged in age from 18-65 yr. On entry to the study, the mean (+/-SD) Hb AIc and plasma glucose levels of the diabetic group (8.60 +/- 2.11% and 142.5 +/- 99.9 mg/dl) were significantly higher than in the control group (4.68 +/- 0.60% and 102.4 +/- 21.7 mg/dl; P less than 0.001) and remained so throughout the study. The mean coefficient of variation for Hb AIc did not differ significantly between the control group and either the diet therapy or insulin therapy diabetic groups. Urine test values averaged over 2-week periods for each diabetic subject showed a high degree of stability. The mean Hb AIc levels for individual diabetic subjects correlated with the mean plasma glucose levels (r = 0.544; P less than 0.001), proportion of 2% urine tests (r = -0.798; P less than 0.001). These data provide further support for Hb AIc as a measure of diabetes control and, in addition, provide the first direct evidence that a single Hb AIc determination in a 3-month period is adequate for this purpose when the subjects are on a stable therapeutic regimen.
对49名糖尿病门诊患者和20名非糖尿病受试者进行了为期14周的每两周一次的糖化血红蛋白(Hb)A1c水平测量。作为糖尿病控制的常规指标,每天进行4次尿液检测,并在早餐后2小时测量血浆葡萄糖浓度。糖尿病组年龄在15至73岁之间,糖尿病病程为6个月至45年。11名受试者仅接受饮食治疗,3名接受口服降糖药治疗,35名接受胰岛素治疗。非糖尿病组年龄在18至65岁之间。在研究开始时,糖尿病组的平均(±标准差)糖化血红蛋白和血浆葡萄糖水平(8.60±2.11%和142.5±99.9mg/dl)显著高于对照组(4.68±0.60%和102.4±21.7mg/dl;P<0.001),并且在整个研究过程中一直如此。对照组与饮食治疗或胰岛素治疗的糖尿病组之间,糖化血红蛋白的平均变异系数没有显著差异。每个糖尿病受试者在2周期间的尿液检测值平均显示出高度的稳定性。个体糖尿病受试者的平均糖化血红蛋白水平与平均血浆葡萄糖水平相关(r = 0.544;P<0.001),与2%尿液检测比例相关(r = -0.798;P<0.001)。这些数据进一步支持了糖化血红蛋白作为糖尿病控制指标的作用,此外,还提供了首个直接证据,即当受试者处于稳定治疗方案时,在3个月内进行一次糖化血红蛋白测定就足以达到此目的。